A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Conditions
Metastatic Solid Tumor · Recurrent Solid Tumor · Advanced Solid Tumor · Urinary Bladder Neoplasm · Triple Negative Breast Cancer · Non-small Cell Lung Cancer · Esophageal Cancer · Pancreatic Cancer · Ovarian Cancer · Cervical Cancer · Head and Neck Squamous Cell Carcinoma · Prostate Cancer · Renal Pelvis Cancer · Bladder Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope National Medical Center, Duarte, California, United States
UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
Florida Cancer Specialists and Research Institute, St. Petersburg, Florida, United States
University of Chicago Hospital, Chicago, Illinois, United States
IU Simon Cancer Center, Indianapolis, Indiana, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids, Michigan, United States
Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Columbia University Irving Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States
START Mountain Region, West Valley City, Utah, United States
St Vincent's Hospital, Darlinghurst, Australia
Linear Clinical Research, Nedlands, Australia
Beijing Cancer hospital, Beijing, China
Sun Yat-sen University Cancer Center, Guangzhou, China
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Institut Gustave Roussy (Igr), Villejuif, France
National Cancer Center Hospital, Chūōku, Japan
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
The Cancer Institute Hospital of JFCR, Kōtō City, Japan
Aichi Cancer Center Hospital, Nagoya, Japan
Asan Medical Center, Seoul, South Korea
Catalan Institute of Oncology Duran i Reynals Hospital, Barcelona, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Hospital Madrid Norte Sanchinarro, Madrid, Spain
Hospital Universitario Virgen Del Rocio, Seville, Spain
St Bartholomew's Hospital, London, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom
Study leads
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company